DLS PHARMAG
DLS PHARMAG, also known as DLS Pharma, is a prominent player in the pharmaceutical industry, headquartered in Italy. Founded in 2005, the company has established a strong presence in major operational regions across Europe and Asia, focusing on innovative drug development and manufacturing. Specialising in high-quality generic and specialty pharmaceuticals, DLS PHARMAG distinguishes itself through its commitment to rigorous quality standards and advanced research methodologies. The company has achieved significant milestones, including several successful product launches that have solidified its market position. With a reputation for excellence and a diverse portfolio, DLS PHARMAG continues to contribute to the healthcare sector, ensuring access to essential medications while maintaining a focus on sustainability and patient care.
DitchCarbon Score
How does DLS PHARMAG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
DLS PHARMAG's score of 3 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
DLS PHARMAG's reported carbon emissions
DLS PHARMAG, headquartered in Italy, currently does not have available carbon emissions data for the most recent year, nor do they have specified reduction targets or climate pledges. Without specific emissions figures or commitments, it is challenging to assess their carbon footprint or climate strategy. However, the absence of data may indicate a need for enhanced transparency and accountability in their environmental practices. As the pharmaceutical industry increasingly prioritises sustainability, DLS PHARMAG may benefit from establishing clear climate commitments and measurable reduction targets to align with industry standards and expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
DLS PHARMAG is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
